益气养阴活血利水法联合康柏西普治疗糖尿病性黄斑水肿的临床研究

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (728 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To evaluate the safety and effectiveness of Yiqi-Yangyin-Huoxue-Lishui combined with Conbercept in the treatment of diabetic macular edema(DME),and to provide more clinical means and ideas for the treatment of DME by the combination of traditional Chinese and Western medicine.Methods A total of 70 DME patients hospitalized in the Department of Ophthalmology,Pingxiang People's Hospital from June 2019 to June 2022 were selected as the research objects.Monocular drug injection was performed in each treatment cycle,only one eye was enrolled in the study.Six patients were followed up,and 64 patients were included in the statistics.They were divided into treatment group (29 cases)and control group(35 cases)according to admission.The treatment group was given intravitreal injection of Compaercept once combined with oral Yiqi-Yangyin-Huoxue-Lishui Chinese medicine set for 3 months.The control group was given intravitreal injection of Compacept once.The best corrected visual acuity (BCVA),central retinal thickness (CRT),traditional Chinese medicine syndrome score and the number of repeated intraocular drug injection were compared between the two groups before treatment and 1,3 and 6 months after treatment.Results The comparison of BCVA,CRT and traditional Chinese medicine syndrome score before and after treatment between the two groups showed statistically significant differences (P＜0.05),while the comparison of BCVA,CRT and traditional Chinese medicine syndrome score between the two groups and their interaction before and after treatment showed no statistically significant differences (P＞0.05).BCVA,CRT and traditional Chinese medicine syndrome score of the treatment group 1 and 3 months after treatment and the control group 1 month after treatment were higher than those before treatment,and the differences were statistically significant (P＜0.05).There was no significant difference in BCVA,CRT and traditional Chinese medicine syndrome scores 3 months after treatment in the control group and 6 months after treatment in the two groups (P＞0.05).CRT at 3 months after treatment rebounded compared with 1 month after treatment.Five cases in the treatment group needed to be re-injected with Compaplomb,less than 15 cases in the control group,and the difference was statistically significant (χ2=4.844,P=0.033).Compared with the average changes of BCVA,CRT and traditional Chinese medicine syndrome score before treatment,the improvement of BCVA,CRT and traditional Chinese medicine syndrome score in the treatment group was always better than that in the control group.In addition,no significant safety issues occurred during treatment in either group.Conclusion The efficacy of Yiqi-Yangyin-Huoxue-Lishui combined with Conbercept in the treatment of DME may be better than that of Conbercept alone,which is helpful to improve postoperative BCVA ands delay the recurrence of macular edema.

Key words： Yiqi-Yangyin-Huoxue-Lishui Conbercept Macular edema Diabetic

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I14/78

[1]	Chen P，zhao W，Wang N，et al.Clinical analysis of fundus fluorescence angiography on diabetic retinapathy[J].Int J Ophthalmol，2007，7（3）：863-863.
[2]	Sennlaub F，Courtois Y，Goureau O.Inducible nitric oxide synthase mediates the change frome retinal to vitreal neovascularization in ischemic retinopathy[J].Clin Invest，2001，107（6）：717-725.
[3]	曾志成，彭俊，蒋鹏飞，等.益气养阴活血利水复方联合玻璃体腔注射康柏西普治疗糖尿病性黄斑水肿疗效观察[J].中国中西医结合杂志，2019，39（3）：270-274.
[4]	中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南（2014 年）[J].中华眼科杂志，2014，50（11）：851-865.
[5]	郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[6]	朱晶，吴超琼，鲁铭，等.中药联合玻璃体腔内注射雷珠单抗治疗糖尿病性黄斑水肿的疗效观察[J].南京中医药大学学报，2015，31（4）：327-330.
[7]	胡元春.补阳汤加减方治疗糖尿病黄斑水肿的临床观察及相关机制研究[D].北京：中国中医科学院，2019.
[8]	Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group.The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumabinjections：report1：visualacuity[J].Ophthalmology，2014，121（5）：1092-1101.
[9]	国家中医药管理局医政司.中医病症诊断疗效标准（中华人民共和国中医药行业标准）[S].北京：中国标准出版社，2023.
[10]	Shams N，Lanchulev T.Role of vascular endothelial growth factor in ocular angiogenesis[J].Opthalmol Clin North Am，2006，39（5）：469-478.
[11]	Introini U，Casalino G.Intravitreal Aflibercept in Diabetic Macular Edem: Long-Term Outcomes[J].Dev Ophthalmol，2017，60：71-77.
[12]	Wells JA，Glassman AR，Ayala AR，et al.Aflibercept,bevacizumab,or ranibizumab for diabetic macular edema[J].N Engl J Med，2015，372（13）：1193-1203.
[13]	Li F，Zhang L，Wang Y，et al.One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema[J].Curr Eye Res，2018，43（2）：218-223.
[14]	Xu Y，Rong A，Xu W，et al.Comparison of 12 -month therapeutic effect of Conbercept and ranibizumab for diabetic macular edema：a real-life clinical practice study[J].BMC Ophthalmol，2017，17（1）：158.
[15]	钱锦，朱蓓菁，姚月蓉，等.唐建明中西医结合治疗糖尿病性黄斑水肿的疗效分析[J].国际眼科杂志，2020，20（5）：856-859.
[16]	王蕾蕾，王宁，冯奕斌，等.中医药治疗糖尿病视网膜病变临床与基础研究进展[J].中国中医眼科杂志，2014，24（3）：227-232.
[17]	接传红，高健生，郭欣璐，等.补气健脾养阴方联合激光治疗糖尿病性黄斑水肿疗效观察[J].陕西中医，2014，35（10）：1303-1305.
[18]	李萍，彭俊，周亚莎，等.彭清华辨治黄斑囊样水肿经验[J].中华中医药杂志，2016，31（11）：4581-4583.
[19]	钱查娇，周玉娟，方巧，等.和营健脾、清热利水解毒法治疗糖尿病黄斑水肿30 例[J].江西中医学院学报，2013，25（5）：32-34.
[20]	仝立国，宋美卿，杨钤，等.黄芪-莪术抗肿瘤定向功效成分群的筛选及作用机制研究[J].中华临床医师杂志（电子版），2018，11（24）：2499-2506.
[21]	吴信华.潜阳育阴颗粒高血压肾保护的功效物质基础研究[D].南京：南京中医药大学，2020.
[22]	赵常英.关于三七的活性成分药理与临床应用功效的相关探讨[J].世界最新医学信息文摘，2016，16（90）：195-196.
[23]	朱瑄.丹参的实验药理研究进展[J].中国现代药物应用.2010，15（4）：230.
[24]	周宏超，高立云，范光丽，等.茯苓酸对SLT-Ⅱe 诱导大鼠肠黏膜微血管内皮细胞分泌细胞因子的影响[J].中国兽医科学，2008，（10）：884-888.
[25]	刘培，彭俊，李书楠，等.益气养阴活血利水法联合康柏西普对非增殖期糖尿病视网膜病变患者视网膜电图的影响[J].陕西中医，2020，41（6）：728-732.